Comparative Pharmacology
Head-to-head clinical analysis: ADPHEN versus OBESTIN 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADPHEN versus OBESTIN 30.
ADPHEN vs OBESTIN-30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adphen is a combination of phentermine hydrochloride and diethylpropion hydrochloride. Phentermine is a sympathomimetic amine that acts as an appetite suppressant by stimulating the hypothalamus to release norepinephrine, thereby reducing food intake. Diethylpropion also has sympathomimetic activity, though its exact mechanism is not fully understood.
ObesTin-30 is a selective serotonin reuptake inhibitor (SSRI) that blocks serotonin reuptake, increasing serotonin levels in the synaptic cleft, which modulates appetite and mood.
5 mg orally once daily, titrated to a maximum of 10 mg once daily as tolerated.
30 mg subcutaneously once daily.
None Documented
None Documented
Terminal elimination half-life is 10-15 hours in adults with normal renal function; prolonged to 20-30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 12 hours (range 10–14 hours) in patients with normal renal function; half-life may be prolonged to >24 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal (70-90% as unchanged drug) with minor biliary (10-15% as metabolites). Fecal elimination is negligible (<5%).
Renal excretion of unchanged drug accounts for approximately 60% of the administered dose; fecal elimination via biliary excretion accounts for approximately 30%, with the remainder as metabolites.
Category C
Category C
Anorexiant
Anorexiant